Leukemias, lymphomas, and other hematologic cancers:

Indications for: Teniposide

Refractory childhood acute lymphoblastic leukemia.

Adults and Children:

See full labeling. Give as slow IV infusion (at least 30–60mins). Patients failing induction therapy with a cytarabine-containing regimen: 165mg/m2 + cytarabine twice weekly for 8 to 9 doses. Refractory to vincristine/prednisone-containing regimen: 250mg/m2 + vincristine weekly for 4 to 8 weeks + oral prednisone for 28 days.

Boxed Warning:

Should be administered under the supervision of an experienced physician. Severe myelosuppression with resulting infection or bleeding may occur. Hypersensitivity reactions.

Teniposide Warnings/Precautions:

Dose-limiting bone marrow suppression. Monitor for hypersensitivity reactions following infusion; have epinephrine available. Risk of hypotension with rapid IV administration. Hepatic dysfunction. Monitor and obtain CBCs with differential, hemoglobin, platelets, renal and hepatic functions before, during, and after therapy. Down syndrome (use reduced dose). Monitor children with hypoalbuminemia. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Teniposide Classification:

Topoisomerase inhibitor.

Teniposide Interactions:

Potentiated by tolbutamide, sodium salicylate, and sulfamethizole. Concomitant vincristine sulfate may cause neuropathy. Concomitant antiemetics in patients given high doses of teniposide may increase risk of CNS depression, hypotension.

Adverse Reactions:

Myelosuppression (leukopenia, neutropenia, thrombocytopenia, anemia), mucositis, GI upset, infection, alopecia, bleeding, rash, fever, hypotension, CNS depression, hypersensitivity reactions (may be fatal).


Formerly known under the brand name Vumon.

How Supplied:

Contact supplier.